Table 1.
Primary blast percentage after AML treatment.
| Demographic | AML subtype Cytogenetic/FISH |
Molecular marker | Initial blast count (%) | Blast count (%) after 1,25-VD3 (80 nM) | Blast count (%) after 5-Azacytidine (5 μM) | Blast count (%) after combination |
|---|---|---|---|---|---|---|
| 30y F | M1, normal | +NPM1, +FLT3-ITD | 14% | 6.88% | 14% | 2.44% |
| 47y M | M4, normal | +NPM1 | 36% | 2.56% | 19.8% | 0.91% |
| 50y F | M5, normal | +NPM1, +FLT3-ITD | 19.3% | 3.85% | 21.8% | 2.35% |
| 32y F | M4, inv.(16) | Normal | 71.2% | 17.1% | 28.2% | 11.0% |
| 53y F | M2, t(8;21)(q22;q22); RUNX1-ETO | +FLT3-TKD | 20.8% | 8.44% | 1.3% | 0.8% |
| A.2568 | +FLT3-ITD | 69.6% | 58.7% | 23.6% | 19% | |
| A.2431 | +FLT3-ITD | 69% | 61.7% | 44.9% | 35.2% |